Innovative solution for kidney patients

Before we get to today’s startup, a few super quick updates:

1. I updated our application form, and it now takes only one minute to complete. We are selective about who we feature, but it is 100% free. If you’re an Israeli founder, apply. If you know any, please send them our way.

2. Though we have been focused on biomed and healthcare in our recent features, we remain sector agnostic. Just wanted to clarify that.

3. Each feature/email will now end with a 2-option poll: does it show exciting potential, or not so much?
   The results of the survey will appear in the following feature/email.

This week’s startup transforms kidney and hypertension care with a patented and certified noninvasive device that restores kidney function. It offers hope to millions of chronic kidney disease patients and dramatically delays the need for dialysis.

Company name: Curespec

Website: curespec.info

What they do (in a sentence):
Curespec developed Nephrospec™, an innovative, noninvasive device that improves kidney function and cuts systolic blood pressure, without surgery, sedation, or hospital stay.

Why now:

• Chronic kidney disease (CKD) affects 850 million people and hypertension >1 billion; current treatments are invasive, expensive, and largely reactive.

• Healthcare payers increasingly incentivize early-stage interventions, creating a favorable reimbursement landscape.

Team highlights:

• Rotem Kaynan (CEO) – 20 years in global med-device commercialization and clinical strategy.

• Avner Spector (Chairman & Co-founder) – 30 years leading med-tech R&D and multiple successful exits.

• Dr Adi Leiba, MD, MHA, FACP (Chief Medical Officer) - Nephrology & Hypertension Specialist.

• Advisory board: Mayo Clinic leaders and senior medical experts, Dr. Amir Lerman & Dr. Lilach O.

Traction:

• Product ready: Nephrospec™ fully developed, CE-marked, and registered in Israel & the Philippines.

• Pilots & early sales: Active programs at Sheba Medical Center (Israel), CHUV (Switzerland), Osaka University (Japan); first commercial systems sold under early-access agreements.

• IP: 4 granted U.S. patents, 2 pending.

• FDA breakthrough device designation under review (De-Novo pathway).

Competitive edge / moats:

• Strong, defensible IP portfolio covering technology, treatment protocols, and CKD/hypertension applications (see above).

• First-mover advantage with validated clinical outcomes and partnerships at top-tier institutions.

Capital raised: $1.3M (excluding grants).
Notable investors: Yoel Carasso, Israel Innovation Authority

Contact:
For investment or business inquiries, contact Rotem Kaynan (CEO) or reply to this message to request an introduction.

Yours,

Tzakhi and the Chosen.Ventures team

PS Let’s connect:

1. If you invest or are looking to invest in Israeli startups, let’s talk. Reply to this email or go ahead and book a time with me on my Calendly. Thanks.

2. If you are in touch with Israeli startups you believe we should feature, let them know about us or introduce them to me. They can also apply here (there is no cost to getting featured).

3. If you would like to partner, sponsor, or collaborate with us in any way, send me a message by replying to this email.

* Disclaimer: The information we share in our emails and on our website is solely for entertainment purposes and should never be considered investment or financial advice. The startups we feature provide us with the information we share about them, and they are solely responsible for its accuracy. The startups we feature may have business and other connections with us or our affiliates.